XML 24 R11.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value of Financial Instruments
9 Months Ended
Sep. 30, 2024
Fair Value of Financial Instruments [Abstract]  
Fair Value of Financial Instruments
Note 5—Fair Value of Financial Instruments

The Company’s financial instruments consist of cash and cash equivalents and warrants.

Pursuant to the requirements of Accounting Standards Codification (“ASC”) Topic 820 “Fair Value Measurement,” the Company’s financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:

Level 1 - Financial instruments with unadjusted quoted prices listed on active market exchanges.

Level 2 - Financial instruments lacking unadjusted, quoted prices from active market exchanges, including over-the-counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.


Level 3 - Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques.

The fair value of the Company’s common and preferred stock warrant liabilities related to the investor warrants issued in the October 2023, October 2022 and April 2024 public offerings was calculated using a Monte Carlo valuation model and was classified as Level 3 in the fair value hierarchy.

The following is a roll-forward of the fair value of the Level 3 warrants:

(in thousands)
     
Balance at December 31, 2022
 
$
6,868
 
Change in fair value
   
755
 
Issuance of Common Stock for exercise of Series I warrants
    (7,623 )
October 17, 2023, issuance of Series J warrants     4,965  
Exercise of Series J warrants     (536 )
Change in fair value     (1,586 )
Balance at December 31, 2023
   
2,843
 
Exercise of Series J warrants
    (1,357 )
April 30, 2024, issuance of common warrants     7,813
 
Exercise of April 2024 warrants
    (1,373 )
Reclassification of April 2024 warrants to equity
    (2,844 )
Change in fair value
    (4,602 )
Balance at September 30, 2024   $ 480